Physician profile
Payal Kumar
NPI 1588271068
$7,505.30
in general payments reported to CMS, 2019-2025
27 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $502 · 2022: $1,187 · 2023: $2,087 · 2024: $2,369 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,622 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,621.59 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,111.13 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,012.65 | 2021-2025 | |
| Lilly USA, LLC | $725.67 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $703.36 | 2021-2025 | Fasenra, Farxiga, Airsupra |
| Amgen INC. | $665.83 | 2021-2025 | Repatha, Otezla, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $533.41 | 2023-2025 | Caplyta |
| Glaxosmithkline, LLC. | $477.21 | 2021-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Astellas Pharma US INC | $382.22 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $380.18 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $321.06 | 2021-2025 | Nexletol |
| Daiichi Sankyo INC. | $289.69 | 2021-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $178.85 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $127.33 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $124.72 | 2023-2024 | |
| Almatica Pharma LLC | $95.29 | 2022-2023 | Gralise, Loreev Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52.88 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.58 | 2023-2025 | Camzyos, Eliquis |
| Otsuka America Pharmaceutical, INC. | $47.19 | 2023-2024 | Nuedexta |
| Ironwood Pharmaceuticals, INC | $40.50 | 2024-2025 | |
| Pfizer INC. | $36.97 | 2024 | |
| Ani Pharmaceuticals, INC. | $25.87 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.75 | 2024 | Ofev |
| Sunovion Pharmaceuticals INC. | $22.71 | 2021 | |
| Intra-Sana Laboratories | $21.44 | 2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Scpharmaceuticals INC. | $20.35 | 2025 | |
| Gilead Sciences, INC. | $18.86 | 2025 | |
| Dexcom, INC. | $16.60 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payal Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.